Next Article in Journal
Healing and Survivorship: What Makes a Difference?
Previous Article in Journal
The Economic Impact on Families When a Child Is Diagnosed with Cancer
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 15
Issue 4
10.3747/co.v15i4.257
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Defining the Optimal Treatment Strategy for Localized Prostate Cancer Patients: A Survey of Ongoing Studies at the National Cancer Institute of Canada Clinical Trials Group

by
W.R. Parulekar
1,*,
M. McKenzie
2,
K.N. Chi
2,
L. Klotz
3,
C. Catton
4,
M. Brundage
5,
K. Ding
1,
A. Hiltz
1,
R. Meyer
1 and
F. Saad
6
1
National Cancer Institute of Canada Clinical Trials Group, Kingston, ON, Canada
2
BC Cancer Agency, Vancouver, BC, Canada
3
Sunnybrook Health Sciences Centre, Toronto, ON, Canada
4
Princess Margaret Hospital, Toronto, ON, Canada
5
Cancer Centre of Southeastern Ontario at Kingston General Hospital, Kingston, ON, Canada
6
CHUM–Hôpital Notre Dame, Montreal, QC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2008, 15(4), 179-184; https://doi.org/10.3747/co.v15i4.257
Submission received: 5 May 2008 / Revised: 6 June 2008 / Accepted: 7 July 2008 / Published: 1 August 2008

Abstract

The designation “clinically localized prostate cancer” comprises a group of biologically heterogeneous tumours with different growth rates and risks of relapse. Because prostate cancer is primarily a disease of older men, treatment selection must take into account the prognosis of the tumour, patient age, comorbidities, side effects of treatment, and patient preferences. Clinical trials must identify the various prognostic groups and test the appropriate treatment strategies within these subgroups.
Keywords: localized prostate cancer; risk estimation; clinical trials localized prostate cancer; risk estimation; clinical trials

Share and Cite

MDPI and ACS Style

Parulekar, W.R.; McKenzie, M.; Chi, K.N.; Klotz, L.; Catton, C.; Brundage, M.; Ding, K.; Hiltz, A.; Meyer, R.; Saad, F. Defining the Optimal Treatment Strategy for Localized Prostate Cancer Patients: A Survey of Ongoing Studies at the National Cancer Institute of Canada Clinical Trials Group. Curr. Oncol. 2008, 15, 179-184. https://doi.org/10.3747/co.v15i4.257

AMA Style

Parulekar WR, McKenzie M, Chi KN, Klotz L, Catton C, Brundage M, Ding K, Hiltz A, Meyer R, Saad F. Defining the Optimal Treatment Strategy for Localized Prostate Cancer Patients: A Survey of Ongoing Studies at the National Cancer Institute of Canada Clinical Trials Group. Current Oncology. 2008; 15(4):179-184. https://doi.org/10.3747/co.v15i4.257

Chicago/Turabian Style

Parulekar, W.R., M. McKenzie, K.N. Chi, L. Klotz, C. Catton, M. Brundage, K. Ding, A. Hiltz, R. Meyer, and F. Saad. 2008. "Defining the Optimal Treatment Strategy for Localized Prostate Cancer Patients: A Survey of Ongoing Studies at the National Cancer Institute of Canada Clinical Trials Group" Current Oncology 15, no. 4: 179-184. https://doi.org/10.3747/co.v15i4.257

Article Metrics

Back to TopTop